Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Idiopathic Pulmonary Fibrosis (ART-IPF)
NCT01969409Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2014
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in idiopathic pulmonary fibrosis (IPF), sponsored by University of Alabama at Birmingham. Started Jan 2014; status: completed.
02
Drugs
rituximab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01969409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01969409.